GRI BIO, Inc. Files 8-K on Security Holder Vote Matters
Ticker: GRI · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1824293
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
GRI BIO (GRIB) holding shareholder vote, expect news soon.
AI Summary
GRI BIO, Inc. filed an 8-K on June 7, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates that GRI BIO, Inc. is engaging its security holders on important corporate decisions, which could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is procedural and reports on a vote of security holders, not a material event like a merger or financial distress.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- June 7, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific matters are being submitted to a vote of security holders?
The filing does not specify the exact matters being voted on, only that the report is being made pursuant to the submission of such matters.
When was GRI BIO, Inc. formerly known as Vallon Pharmaceuticals, Inc.?
The date of the name change from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc. was September 10, 2020.
What is the primary business of GRI BIO, Inc.?
GRI BIO, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are GRI BIO, Inc.'s principal executive offices located?
The principal executive offices are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the fiscal year end for GRI BIO, Inc.?
The fiscal year end for GRI BIO, Inc. is December 31st.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-06-07 16:06:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20240607.htm (8-K) — 27KB
- val-20240607_g1.jpg (GRAPHIC) — 16KB
- val-20240607_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000057.txt ( ) — 179KB
- val-20240607.xsd (EX-101.SCH) — 2KB
- val-20240607_lab.xml (EX-101.LAB) — 22KB
- val-20240607_pre.xml (EX-101.PRE) — 13KB
- val-20240607_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On June 7, 2024, at 11:00 a.m. Eastern Time, GRI Bio, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") virtually at www.virtualshareholdermeeting.com/GRI2024SM2. Of the Company's 3,774,488 shares of common stock issued and outstanding and eligible to vote as of the record date of May 1, 2024, a quorum of 1,727,613 shares, or approximately 45.8% of the eligible shares, was present or represented by proxy. Each of the matters set forth below is described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on May 9, 2024. The following actions were taken at the Special Meeting: Proposal 1 The proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio within the range of not less than one-for-two and not more than one-for-fifteen, with the exact ratio to be set within this range by the Company's board of directors (the "Board") in its sole discretion (without reducing the authorized number of shares of Company common stock) and with the Board able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by the Company's stockholders in its sole discretion, was approved by a majority of the votes cast by Company stockholders at the Special Meeting. Votes For Votes Against Votes Abstained Broker Non-Votes 1,417,003 310,490 120 0 Proposal 2 The proposal to approve a postponement or adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1, was approved by a majority of the votes cast by Company stockholders at the Special Meeting. Votes For Votes Against Votes Abstained Broker Non-Votes 1,427,587 270,321 29,705 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 7, 2024 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer